We included a total of 108 participants on the AD continuum (Aβ+ CN/MC/AD) and 43 control participants (Aβ- CN) with longitudinal tau-PET and a baseline florbetapir-PET measure. This evidence concerns the gene MAPT and Alzheimer disease.